<p>国会资产管理公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，第三季度其在 Inspire Medical Systems, Inc.（纽约证券交易所代码：INSP - 免费报告）的持股减少了 96.4%。该基金在出售了 359,846 股后，持有该公司 13,501 股股票。截至其最近向证券交易委员会（SEC）提交的文件，国会资产管理公司在 Inspire Medical Systems 的持股价值为 1,002,000 美元。</p>
<ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
<p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。高盛集团在第一季度将其在 Inspire Medical Systems 的持仓提高了 57.9%。高盛集团目前持有该公司 51,422 股股票，价值 8,190,000 美元，此前在该期间内又增持了 18,857 股。德克萨斯州永久学校基金公司在第二季度将其在 Inspire Medical Systems 的持仓增加了 42.2%。德克萨斯州永久学校基金公司目前持有该公司 40,042 股股票，价值 5,196,000 美元，此前又购买了 11,892 股。Nordea Investment Management AB 在第二季度购买了 Inspire Medical Systems 的新股份，价值 1,634,000 美元。Bayforest Capital Ltd 在第一季度将其在 Inspire Medical Systems 的持仓增加了 2,465.9%。Bayforest Capital Ltd 目前持有该公司 5,491 股股票，价值 875,000 美元，此前在上个季度又购买了 5,277 股。最后，CW Advisors LLC 在第二季度将其在 Inspire Medical Systems 的持仓提高了 45.3%。CW Advisors LLC 目前持有该公司 49,960 股股票，价值 6,484,000 美元，此前又购买了 15,576 股。94.91% 的股票由机构投资者和对冲基金持有。</p>
<h2>Inspire Medical Systems 股票表现</h2>
<p>INSP 的股票在周二开盘价为 97.70 美元。该公司的市值为 28.4 亿美元，市盈率为 66.46，市盈增长比率为 11.12，贝塔值为 0.69。Inspire Medical Systems, Inc.的 52 周最低价为 70.77 美元，52 周最高价为 216.01 美元。该股票的 50 日移动平均价格为 99.98 美元，200 日移动平均价格为 102.96 美元。</p>
<ul>
<li>Inspire Medical 在突破后上涨 15%，分析师称其为买入</li>
</ul>
<p>Inspire Medical Systems（纽约证券交易所代码：INSP - 获取免费报告）最后一次公布财报是在 11 月 3 日，周一。该公司报告本季度每股收益（EPS）为 0.38 美元，超出市场共识预期的（0.15 美元）0.53 美元。该公司本季度的收入为 2.245 亿美元，而分析师预期为 2.2039 亿美元。Inspire Medical Systems 的股本回报率为 9.41%，净利润率为 5.05%。Inspire Medical Systems 的季度收入同比增长 10.5%。在去年同期，该公司每股收益为 0.60 美元。平均而言，股票分析师预测 Inspire Medical Systems, Inc.今年将发布 2.16 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对 INSP 发表了评论。瑞穗证券在 12 月 17 日的研究报告中将 Inspire Medical Systems 的目标价格从 110.00 美元上调至 130.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 11 月 26 日的报告中将 Inspire Medical Systems 的评级从 “持有” 上调至 “买入”，并将该股票的目标价格从 128.00 美元上调至 165.00 美元。Stifel Nicolaus 在 11 月 24 日的报告中为 Inspire Medical Systems 设定了 110.00 美元的价格目标，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 10 日的研究报告中重申了对 Inspire Medical Systems 股票的 “卖出（d+）” 评级。最后，富国银行在 11 月 4 日的报告中将 Inspire Medical Systems 的评级从 “等权重” 上调至 “超配”，并将该股票的目标价格从 101.00 美元下调至 90.00 美元。共有 11 位分析师对该股票给予了买入评级，7 位给予了持有评级，1 位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 138.88 美元。</p>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p><strong>阅读我们关于 Inspire Medical Systems 的最新研究报告</strong></p>
<h2>内部活动</h2>
<p>在其他新闻中，董事 Shawn Mccormick 在 11 月 28 日的交易中出售了 2,000 股该股票。该股票以 127.48 美元的平均价格出售，总价值为 254,960.00 美元。出售完成后，该董事在公司持有 26,046 股股票，价值 3,320,344.08 美元。这代表其持股减少了 7.13%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。当前 2.30% 的股票由内部人士持有。</p>
<h2>Inspire Medical Systems 新闻摘要</h2>
<p>以下是本周影响 Inspire Medical Systems 的主要新闻故事：</p>
<ul>
<li>积极情绪：Zacks 发布了一份看涨报告，认为由于 Inspire V 临床数据强劲、报销可见性改善和成本控制，INSP 仍然值得持有，尽管面临库存和 GLP-1 的挑战。Zacks：维持 INSP 股票</li>
<li>积极情绪：报告显示分析师提高了目标价（MSN 报道提高了 12.65% 至 $144.32），这表明在近期疲软后，卖方对上涨的信心有所增强。MSN：目标价上调</li>
<li>消极情绪：今天提交或宣布了多起证券集体诉讼和投资者通知，指控与产品延迟、医疗保险计费软件问题和 Inspire V 库存过剩相关的披露失败；数十家原告律师事务所正在征求主原告动议，截止日期为 2026 年 1 月 5 日——这增加了法律风险、潜在和解以及短期股价压力。BLB&amp;G 提交 Rosen 通知 Hagens Berman 警报</li>
<li>消极情绪：许多其他原告律师事务所（BFA Law、Glancy Prongay &amp; Murray、The Gross Law Firm、Faruqi &amp; Faruqi、Schall、Bronstein Gewirtz 等）发布提醒，鼓励投资者寻求主原告角色——这一系列通知加大了头条风险，并可能在诉讼展开时延长波动性。MarketWatch / BFA Glancy 通知</li>
</ul>
<h2>关于 Inspire Medical Systems</h2>
<p>(免费报告)</p>
<p>Inspire Medical Systems, Inc 是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品 Inspire® 系统，通过对舌下神经进行定向刺激，以维持睡眠期间的气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
<p>Inspire 系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Inspire Medical Systems</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
<p><strong>想看看其他对 INSP 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Inspire Medical Systems, Inc. (NYSE:INSP - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Inspire Medical Systems 吗？</h2>
<p>在考虑投资 Inspire Medical Systems 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛市场关注之前立即购买……而 Inspire Medical Systems 并不在名单上。</p>
<p>尽管 Inspire Medical Systems 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

启迪医疗

<p>国会资产管理公司在第三季度大幅减少了对启迪医疗的持股，降幅达到 96.4%，目前持有价值 100 万美元的股份。其他机构投资者也进行了头寸调整，高盛将其持股增加了 57.9%。启迪医疗的股票表现显示市值为 28.4 亿美元，并且最近的财报超出预期。分析师的评级意见不一，普遍共识为 “适度买入”，目标价格为 138.88 美元</p>

<p>Congress Asset Management Co. trimmed its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 96.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,501 shares of the company's stock after selling 359,846 shares during the quarter. Congress Asset Management Co.'s holdings in Inspire Medical Systems were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>国会资产管理公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，第三季度其在 Inspire Medical Systems, Inc.（纽约证券交易所代码：INSP - 免费报告）的持股减少了 96.4%。该基金在出售了 359,846 股后，持有该公司 13,501 股股票。截至其最近向证券交易委员会（SEC）提交的文件，国会资产管理公司在 Inspire Medical Systems 的持股价值为 1,002,000 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period. Texas Permanent School Fund Corp grew its holdings in Inspire Medical Systems by 42.2% in the second quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company's stock worth $5,196,000 after purchasing an additional 11,892 shares during the period. Nordea Investment Management AB bought a new stake in Inspire Medical Systems in the second quarter valued at $1,634,000. Bayforest Capital Ltd increased its stake in Inspire Medical Systems by 2,465.9% in the first quarter. Bayforest Capital Ltd now owns 5,491 shares of the company's stock valued at $875,000 after purchasing an additional 5,277 shares in the last quarter. Finally, CW Advisors LLC raised its holdings in shares of Inspire Medical Systems by 45.3% during the second quarter. CW Advisors LLC now owns 49,960 shares of the company's stock valued at $6,484,000 after purchasing an additional 15,576 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。高盛集团在第一季度将其在 Inspire Medical Systems 的持仓提高了 57.9%。高盛集团目前持有该公司 51,422 股股票，价值 8,190,000 美元，此前在该期间内又增持了 18,857 股。德克萨斯州永久学校基金公司在第二季度将其在 Inspire Medical Systems 的持仓增加了 42.2%。德克萨斯州永久学校基金公司目前持有该公司 40,042 股股票，价值 5,196,000 美元，此前又购买了 11,892 股。Nordea Investment Management AB 在第二季度购买了 Inspire Medical Systems 的新股份，价值 1,634,000 美元。Bayforest Capital Ltd 在第一季度将其在 Inspire Medical Systems 的持仓增加了 2,465.9%。Bayforest Capital Ltd 目前持有该公司 5,491 股股票，价值 875,000 美元，此前在上个季度又购买了 5,277 股。最后，CW Advisors LLC 在第二季度将其在 Inspire Medical Systems 的持仓提高了 45.3%。CW Advisors LLC 目前持有该公司 49,960 股股票，价值 6,484,000 美元，此前又购买了 15,576 股。94.91% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Inspire Medical Systems Stock Performance</h2>
<div class="lb-trans"><h2>Inspire Medical Systems 股票表现</h2>
</div><p>Shares of INSP opened at $97.70 on Tuesday. The firm has a market capitalization of $2.84 billion, a P/E ratio of 66.46, a P/E/G ratio of 11.12 and a beta of 0.69. Inspire Medical Systems, Inc. has a 52 week low of $70.77 and a 52 week high of $216.01. The stock has a 50 day moving average price of $99.98 and a two-hundred day moving average price of $102.96.</p>
<div class="lb-trans"><p>INSP 的股票在周二开盘价为 97.70 美元。该公司的市值为 28.4 亿美元，市盈率为 66.46，市盈增长比率为 11.12，贝塔值为 0.69。Inspire Medical Systems, Inc.的 52 周最低价为 70.77 美元，52 周最高价为 216.01 美元。该股票的 50 日移动平均价格为 99.98 美元，200 日移动平均价格为 102.96 美元。</p>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Inspire Medical 在突破后上涨 15%，分析师称其为买入</li>
</ul>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million for the quarter, compared to analysts' expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.Inspire Medical Systems's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. On average, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>Inspire Medical Systems（纽约证券交易所代码：INSP - 获取免费报告）最后一次公布财报是在 11 月 3 日，周一。该公司报告本季度每股收益（EPS）为 0.38 美元，超出市场共识预期的（0.15 美元）0.53 美元。该公司本季度的收入为 2.245 亿美元，而分析师预期为 2.2039 亿美元。Inspire Medical Systems 的股本回报率为 9.41%，净利润率为 5.05%。Inspire Medical Systems 的季度收入同比增长 10.5%。在去年同期，该公司每股收益为 0.60 美元。平均而言，股票分析师预测 Inspire Medical Systems, Inc.今年将发布 2.16 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages have recently commented on INSP. Mizuho raised their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 17th. Truist Financial upgraded Inspire Medical Systems from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their price target for the stock from $128.00 to $165.00 in a report on Wednesday, November 26th. Stifel Nicolaus set a $110.00 price objective on Inspire Medical Systems and gave the company a &#34;buy&#34; rating in a report on Monday, November 24th. Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Inspire Medical Systems in a research report on Wednesday, December 10th. Finally, Wells Fargo &amp; Company upgraded Inspire Medical Systems from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and cut their target price for the stock from $101.00 to $90.00 in a report on Tuesday, November 4th. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $138.88.</p>
<div class="lb-trans"><p>几家券商最近对 INSP 发表了评论。瑞穗证券在 12 月 17 日的研究报告中将 Inspire Medical Systems 的目标价格从 110.00 美元上调至 130.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 11 月 26 日的报告中将 Inspire Medical Systems 的评级从 “持有” 上调至 “买入”，并将该股票的目标价格从 128.00 美元上调至 165.00 美元。Stifel Nicolaus 在 11 月 24 日的报告中为 Inspire Medical Systems 设定了 110.00 美元的价格目标，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 10 日的研究报告中重申了对 Inspire Medical Systems 股票的 “卖出（d+）” 评级。最后，富国银行在 11 月 4 日的报告中将 Inspire Medical Systems 的评级从 “等权重” 上调至 “超配”，并将该股票的目标价格从 101.00 美元下调至 90.00 美元。共有 11 位分析师对该股票给予了买入评级，7 位给予了持有评级，1 位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 138.88 美元。</p>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p><strong>Read Our Latest Research Report on Inspire Medical Systems</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Inspire Medical Systems 的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Shawn Mccormick 在 11 月 28 日的交易中出售了 2,000 股该股票。该股票以 127.48 美元的平均价格出售，总价值为 254,960.00 美元。出售完成后，该董事在公司持有 26,046 股股票，价值 3,320,344.08 美元。这代表其持股减少了 7.13%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。当前 2.30% 的股票由内部人士持有。</p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>Inspire Medical Systems 新闻摘要</h2>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本周影响 Inspire Medical Systems 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Zacks published a bullish note arguing INSP remains worth holding due to strong Inspire V clinical data, improving reimbursement visibility and cost control despite inventory and GLP‑1 headwinds. Zacks: Retain INSP Stock</li>
<li>Positive Sentiment: An analyst price‑target increase was reported (MSN coverage of a 12.65% raise to $144.32), signaling some sell‑side conviction on upside after recent weakness. MSN: Price Target Increase</li>
<li>Negative Sentiment: Multiple securities class actions and investor notices were filed or announced today, alleging disclosure failures tied to product delays, Medicare billing software issues and an Inspire V inventory glut; dozens of plaintiff firms are soliciting lead‑plaintiff motions with a January 5, 2026 deadline — this increases legal exposure, potential settlements and short‑term share pressure. BLB&amp;G FilingRosen NoticeHagens Berman Alert</li>
<li>Negative Sentiment: Numerous additional plaintiff firms (BFA Law, Glancy Prongay &amp; Murray, The Gross Law Firm, Faruqi &amp; Faruqi, Schall, Bronstein Gewirtz, etc.) issued reminders encouraging investors to seek lead‑plaintiff roles — the flurry of notices amplifies headline risk and could prolong volatility as the litigation unfolds. MarketWatch / BFAGlancy Notice</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Zacks 发布了一份看涨报告，认为由于 Inspire V 临床数据强劲、报销可见性改善和成本控制，INSP 仍然值得持有，尽管面临库存和 GLP-1 的挑战。Zacks：维持 INSP 股票</li>
<li>积极情绪：报告显示分析师提高了目标价（MSN 报道提高了 12.65% 至 $144.32），这表明在近期疲软后，卖方对上涨的信心有所增强。MSN：目标价上调</li>
<li>消极情绪：今天提交或宣布了多起证券集体诉讼和投资者通知，指控与产品延迟、医疗保险计费软件问题和 Inspire V 库存过剩相关的披露失败；数十家原告律师事务所正在征求主原告动议，截止日期为 2026 年 1 月 5 日——这增加了法律风险、潜在和解以及短期股价压力。BLB&amp;G 提交 Rosen 通知 Hagens Berman 警报</li>
<li>消极情绪：许多其他原告律师事务所（BFA Law、Glancy Prongay &amp; Murray、The Gross Law Firm、Faruqi &amp; Faruqi、Schall、Bronstein Gewirtz 等）发布提醒，鼓励投资者寻求主原告角色——这一系列通知加大了头条风险，并可能在诉讼展开时延长波动性。MarketWatch / BFA Glancy 通知</li>
</ul>
</div><h2>About Inspire Medical Systems</h2>
<div class="lb-trans"><h2>关于 Inspire Medical Systems</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>Inspire Medical Systems, Inc 是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品 Inspire® 系统，通过对舌下神经进行定向刺激，以维持睡眠期间的气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Inspire Medical Systems</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INSP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 INSP 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Inspire Medical Systems, Inc. (NYSE:INSP - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Inspire Medical Systems 吗？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Inspire Medical Systems 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛市场关注之前立即购买……而 Inspire Medical Systems 并不在名单上。</p>
</div><p>While Inspire Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Inspire Medical Systems 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Congress Asset Management Co.在启迪医疗系统公司（Inspire Medical Systems, Inc. $INSP）中持有价值 100 万美元的股票